Allecra Therapeutics Announces Positive Top-Line Results for Phase 3 ALLIUM Clinical Trial of EXBLIFEP® for Complicated Urinary Tract Infections
EXBLIFEP demonstrated superiority in the primary endpoint of clinical cure and microbiological eradication at test-of-cure over piperacillin-tazobactam EXBLIFEP safety profile was comparable to piperacillin-tazobactam SAINT-LOUIS, France and WEIL AM RHEIN, Germany, Feb. 25, 2020 (GLOBE NEWSWIRE) — Allecra Therapeutics today announced that its investigational product EXBLIFEP (cefepime-enmetazobactam) met the U.S. Food and Drug Administration (FDA) […]